Protocol Ledger

NCT04843761 · Phase III · COMPLETED

ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19

Interventional Phase III clinical trial protocol NCT04843761 sponsored by National Institute of Allergy and Infectious Diseases (NIAID) in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-04-20 Enrollment: 473 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04843761
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)473 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04843761
Protocol FieldVerified Registry Value
NCT IdentifierNCT04843761
Consolidated Lead SponsorNational Institute of Allergy and Infectious Diseases (NIAID)
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment473 participants (ACTUAL)
Registered Start Date2021-04-20
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI